


Ask a doctor about a prescription for DONEPEZIL FLAS PHARMA COMBIX 10 mg ORALLY DISINTEGRATING TABLETS
Package Leaflet: Information for the User
Donepezil Flas Pharma Combix 10 mg Orodispersible Tablets EFG
Donepezil, hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Donepezil Flas Pharma Combix (hydrochloride of donepezil) belongs to a group of medicines called acetylcholinesterase inhibitors. Hydrochloride of donepezil increases the levels in the brain of a substance related to memory (acetylcholine), by means of decreasing the speed of decomposition of this substance.
It is used for the treatment of the symptoms of Alzheimer's disease of mild to moderately severe. The symptoms include increased memory loss, confusion, and changes in behavior.
Do not take Donepezil Flas Pharma Combix
Warnings and precautions
Consult your doctor or pharmacist before starting to take Donepezil Flas Pharma Combix if you have or have had:
You should avoid taking this medicine with other acetylcholinesterase inhibitors and other agonists or antagonists of the cholinergic system.
Taking Donepezil Flas Pharma Combix with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken or may have to take any other medicines, especially if you are taking any of the following medicines:
In case of surgical intervention with general anesthesia, you should inform your doctor that you are taking donepezil orodispersible tablets, as this may affect the amount of anesthetic needed.
Donepezil orodispersible tablets can be used in patients with mild to moderate kidney or liver disease. Inform your doctor if you have any kidney or liver disease. Patients with severe liver disease should not take donepezil orodispersible tablets.
Taking Donepezil Flas Pharma Combix with food, drinks, and alcohol
Place the tablet on the tongue and let it dissolve. Swallow with or without water.
Donepezil orodispersible tablets should not be taken with alcohol, as alcohol may alter the effect of this medicine.
Pregnancy, breast-feeding, and fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take donepezil orodispersible tablets if you are pregnant or think you may be pregnant.
Do not take donepezil orodispersible tablets if you are breast-feeding.
Driving and using machines
Your illness may affect your ability to drive or use machines, and you should not carry out these activities unless your doctor tells you it is safe to do so. Donepezil orodispersible tablets may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose. If you experience these effects, do not drive or use machines.
Donepezil Flas Pharma Combix contains aspartame
This medicine may be harmful for people with phenylketonuria because it contains aspartame, which is a source of phenylalanine.
Donepezil Flas Pharma Combix contains glucose
This medicine contains glucose. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Follow exactly the administration instructions of this medicine indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Donepezil orodispersible tablets are administered orally. The tablet should be placed on the tongue and allowed to dissolve before swallowing with or without water.
Treatment with donepezil orodispersible tablets starts with a 5 mg tablet, taken once a day, at night, immediately before bedtime. After one month of treatment, your doctor may indicate an increase in the dose to 10 mg, once a day, at night. The maximum recommended dose is 10 mg per day.
If you have abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend that you take Donepezil Flas Pharma Combix in the morning.
If you have mild or moderate liver or kidney disease, you can take donepezil orodispersible tablets. Inform your doctor before starting treatment if you have liver or kidney problems. Patients with severe liver disease should not take donepezil orodispersible tablets.
Use in children
Donepezil orodispersible tablets are not recommended for use in children.
If you take more Donepezil Flas Pharma Combix than you should
If you have taken more donepezil orodispersible tablets than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, telephone: 91 562 04 20, indicating the medicine and the amount used.
The symptoms of overdose may include feeling sick, drooling, sweating, decreased heart rate, low blood pressure (dizziness or fainting when standing up), breathing problems, loss of consciousness, and seizures.
If you forget to take Donepezil Flas Pharma Combix
Do not take a double dose to make up for forgotten doses.
If you stop taking Donepezil Flas Pharma Combix
Do not stop taking donepezil orodispersible tablets unless your doctor tells you to. If you stop taking donepezil orodispersible tablets, the benefits of treatment will gradually disappear.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been reported by people taking donepezil orodispersible tablets.
Contact your doctor if you have any of these side effects during treatment with donepezil orodispersible tablets.
Serious side effects:
You should inform your doctor immediately if you notice any of the following serious side effects, as you may need urgent medical treatment.
The estimated frequency of occurrence of side effects is as follows:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Frequency not known:
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Donepezil Flas Pharma Combix
Appearance of the product and contents of the pack
Donepezil Flas Pharma Combix 10 mg is presented in orodispersible tablets, i.e., they dissolve in the mouth. The tablets are yellow to yellowish in color, round, with beveled edges, smooth on both sides.
Donepezil Flas Pharma Combix 10 mg orodispersible tablets are presented in Alu/Alu blister packs. Each pack contains 28 or 56 orodispersible tablets.
Not all pack sizes may be marketed.
Marketing authorization holder
Laboratorios Combix, S.L.U.
C/Badajoz, 2. Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
Date of last revision of this leaflet:November 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for DONEPEZIL FLAS PHARMA COMBIX 10 mg ORALLY DISINTEGRATING TABLETS – subject to medical assessment and local rules.